Reed M D, Aronoff S C, Stern R C, Yamashita T S, Myers C M, Friedhoff L T, Blumer J L
Pediatr Pulmonol. 1986 Sep-Oct;2(5):282-6. doi: 10.1002/ppul.1950020506.
The single-dose pharmacokinetics of aztreonam was evaluated in 10 clinically stable subjects with cystic fibrosis. Each child received 30 mg aztreonam/kg intravenously over 2 to 3 minutes. Multiple timed blood samples were obtained over 8 hours for determination of aztreonam elimination kinetics; all urine excreted for 24 hours was collected in timed aliquots for the determination of aztreonam and its microbiologically inactive metabolite, SQ 26,992. Aztreonam pharmacokinetic parameters were determined by model-independent methods. Mean t1/2, steady-state volume distribution, and body clearance were 1.3 hr, 0.25 L/kg, and 127.2 ml/min/1.73m2, respectively. In 9 of the 10 subjects, two-compartment pharmacokinetic analysis was possible and compared favorably with model-independent parameter estimates. Twenty-four-hour urinary recovery of aztreonam was 76.3% of the administered dose; 2.6% was recovered as the metabolite SQ 26,992. The renal clearance of aztreonam averaged 92.5 ml/min/1.73m2. When these data are combined with in vitro susceptibility data for aztreonam against Pseudomonas aeruginosa isolated from the sputum of patients with cystic fibrosis, a dose of 200 mg aztreonam/kg/day divided six hourly would be predicted to maintain serum concentrations above the minimum inhibitory concentration (MIC) for these organisms for the majority of the dosing interval.
对10名临床病情稳定的囊性纤维化患者进行了氨曲南单剂量药代动力学评估。每个儿童在2至3分钟内静脉注射30mg/kg氨曲南。在8小时内采集多个定时血样以测定氨曲南的消除动力学；收集24小时内定时排出的所有尿液，用于测定氨曲南及其微生物学无活性代谢物SQ 26,992。氨曲南药代动力学参数采用非模型依赖方法测定。平均半衰期、稳态分布容积和机体清除率分别为1.3小时、0.25L/kg和127.2ml/min/1.73m²。在10名受试者中的9名中，可以进行二室药代动力学分析，且与非模型依赖参数估计值相比结果良好。氨曲南24小时尿回收率为给药剂量的76.3%；2.6%以代谢物SQ 26,992的形式回收。氨曲南的肾清除率平均为92.5ml/min/1.73m²。当将这些数据与氨曲南对从囊性纤维化患者痰液中分离出的铜绿假单胞菌的体外药敏数据相结合时，预计每日200mg/kg氨曲南分六次给药可使血清浓度在大多数给药间隔内维持在这些微生物的最低抑菌浓度（MIC）以上。
